CRISPR Therapeutics AG
NASDAQ:CRSP · NASDAQ Global Market
+$1.43 today
Vol 1.94M · Avg 1.70M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CRSP · Revenue to Net Income
Key Ratios
Analysis
$4.1M of revenue converted into -$568.5M of net income for the selected period. Gross margin is -5693.0% and net margin is -14725.4%, showing how much revenue survives after costs and taxes. EPS is $-6.22, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M -90.0% | $35.0M -90.5% | $370.0M +84762.4% | $436.0K -100.0% | $913.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $233.0M +111.3% | $110.3M -15.4% | $130.3M +18.1% | $110.3M +9.0% | $101.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$229.4M -204.9% | -$75.3M -131.4% | $239.8M +318.3% | -$109.8M -113.5% | $811.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | -6537.0% -6322.0pp | -215.0% -279.8pp | 64.8% +25251.5pp | -25186.7% -25275.6pp | 88.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $265.3M -17.3% | $320.7M -17.2% | $387.3M -16.1% | $461.6M +35.6% | $340.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $73.5M +0.8% | $73.0M -4.2% | $76.2M -25.7% | $102.5M +2.8% | $99.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $338.9M -13.4% | $391.3M -15.4% | $462.3M -17.9% | $563.3M +28.5% | $438.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $19.5M +1.1% | $19.3M -2.9% | $19.8M -17.9% | $24.2M +34.6% | $18.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$558.5M -62.6% | -$343.4M -162.4% | -$130.9M +79.1% | -$626.3M -257.6% | $397.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -15911.3% -14930.1pp | -981.2% -945.8pp | -35.4% +143617.8pp | -143653.2% -143696.7pp | 43.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$568.3M -21.8% | -$466.6M -109.7% | -$222.5M +66.9% | -$673.2M -280.2% | $373.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -16191.4% -14858.4pp | -1333.0% -1272.9pp | -60.1% +154334.6pp | -154394.7% -154435.6pp | 40.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$9.6M -109.3% | $103.9M +44.7% | $71.8M +216.9% | $22.7M +277.5% | $6.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$578.0M -59.4% | -$362.7M -140.6% | -$150.7M +76.8% | -$650.5M -271.4% | $379.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -16466.2% -15430.1pp | -1036.2% -995.5pp | -40.7% +149156.5pp | -149197.2% -149238.8pp | 41.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $3.6M +1.3% | $3.6M +24.2% | $2.9M +988.6% | -$325.0K -117.4% | $1.9M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$581.6M -58.8% | -$366.3M -138.4% | -$153.6M +76.4% | -$650.2M -272.2% | $377.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -16569.8% -15523.3pp | -1046.4% -1004.9pp | -41.5% +149081.2pp | -149122.7% -149164.1pp | 41.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$6 -49.1% | -$4 -123.7% | -$2 +76.8% | -$8 -268.2% | $5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$6 -49.1% | -$4 -123.7% | -$2 +76.8% | -$8 -277.9% | $5 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $89.9M +6.6% | $84.4M +6.5% | $79.2M +1.9% | $77.7M +2.4% | $75.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $89.9M +6.6% | $84.4M +6.5% | $79.2M +1.9% | $77.7M -3.3% | $80.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$11.54B
Krystal Biotech, Inc.
NASDAQ:KRYS
$10.35B
Cytokinetics, Incorporated
NASDAQ:CYTK
$9.73B
Nuvalent, Inc.
NASDAQ:NUVL
$9.08B
TG Therapeutics, Inc.
NASDAQ:TGTX
$8.26B
Vaxcyte, Inc.
NASDAQ:PCVX
$7.58B
Metsera, Inc.
MTSR
$7.43B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.52B
Akero Therapeutics, Inc.
AKRO
$4.50B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CRSP generate?
CRISPR Therapeutics AG (CRSP) reported $3.51M of revenue in fiscal 2025.
Is CRSP profitable?
CRISPR Therapeutics AG (CRSP) reported -$581,599,000.00 of net income, with a net margin of -16569.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.